Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5091199 | 0.89 | PTGDR2 (0.59) | PTGDR2MAPTUSP2PTGER1TDP1 | |
| SCHEMBL5089021 | 0.87 | PTGDR2 (0.53) | PTGDR2MAPTUSP2GSK3B | |
| SCHEMBL5094242 | 0.86 | PTGDR2 (0.55) | PTGDR2MAPTUSP2GSK3BPTGER1 | |
| SCHEMBL5088958 | 0.84 | PTGDR2 (0.50) | PTGDR2MAPTUSP2PTGER1 | |
| SCHEMBL5091226 | 0.82 | PTGDR2 (0.53) | PTGDR2MAPTUSP2GSK3BALDH1A1 | |
| SCHEMBL5098954 | 0.82 | PTGDR2 (0.55) | PTGDR2MAPTUSP2ALDH1A1RAB9A | |
| SCHEMBL5099579 | 0.81 | PTGDR2 (0.64) | PTGDR2MAPTUSP2PTGER1TDP1 | |
| SCHEMBL5091200 | 0.79 | LMNA (0.57) | PTGDR2MAPTUSP2TDP1L3MBTL1 | |
| SCHEMBL5099650 | 0.79 | PTGDR2 (0.47) | PTGDR2MAPTUSP2GSK3BPTGER1 | |
| SCHEMBL5091264 | 0.79 | PTGDR2 (0.53) | PTGDR2MAPTUSP2TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7323570-B2 | Farnesyltransferase inhibitors | ABBOTT LABORATORIES (US) | 2008-01-29 | — | — | US | disclosed |
| US-7211595-B2 | Farnesyltransferase inhibitors | ABBOTT LABORATORIES (US) | 2007-05-01 | — | — | US | disclosed |
| US-20060264476-A1 | Farnesyltransferase Inhibitors | ABBVIE INC. | 2006-11-23 | — | — | US | disclosed |
| EP-1339695-B1 | FARNESYLTRANSFERASE INHIBITORS | ABBOTT LAB (US) | 2006-04-19 | — | — | EP | disclosed |
| US-20030087940-A1 | Farnesyltransferase inhibitors | ABBVIE INC. | 2003-05-08 | — | — | US | disclosed |
| US-20020115640-A1 | Such as 4-(((6-chloro-2-(3-chlorophenyl)-3-pyridinyl) methoxy)(1-methyl-1H-imidazol-5-yl)methyl)benzonitrile; anticancer agents | ABBOTT LABORATORIES | 2002-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115640-A1 | Such as 4-(((6-chloro-2-(3-chlorophenyl)-3-pyridinyl) methoxy)(1-methyl-1H-imidazol-5-yl)methyl)benzonitrile; anticancer agents | FNTB, FNTA, ACAT2 | PTGDR2 4612/4885MAPT 2757/4885USP2 3378/4885 |
| US-20060264476-A1 | Farnesyltransferase Inhibitors | FNTB, FNTA, FDPS | PTGDR2 3285/4885MAPT 2033/4885USP2 2916/4885 |
| US-20030087940-A1 | Farnesyltransferase inhibitors | FNTB, FNTA, FDPS | PTGDR2 3106/4885MAPT 2623/4885USP2 2801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.